NASDAQ
MLND

Millendo Therapeutics, Inc

Prices are adjusted according to historical splits.

Millendo Therapeutics, Inc Stock Price

Vitals

Today's Low:
$1.9902
Today's High:
$2.1900
Open Price:
$1.9999
52W Low:
$1.26
52W High:
$9.88
Prev. Close:
$1.9500
Volume:
19867

Company Statistics

Market Cap.:
$0.030 billion
Book Value:
2.33
Revenue TTM:
$0.000 billion
Operating Margin TTM:
0%
Gross Profit TTM:
$0.000 billion
Gross Profit TTM:
$0.000 billion
Profit Margin:
0%
Return on Assets TTM:
-47.15%
Return on Equity TTM:
-94.03%

Company Profile

Millendo Therapeutics, Inc had its IPO on 2012-11-12 under the ticker symbol MLND.

The company operates in the sector and industry. Millendo Therapeutics, Inc has a staff strength of 37 employees.

Stock update

Shares of Millendo Therapeutics, Inc opened at $2 at the start of the last trading session i.e. 2022-11-02.

The stocks traded within a range of $1.99 - $2.19, and closed at $2.12.

This is a +8.72% increase from the previous day's closing price.

A total volume of 19,867 shares were traded at the close of the day’s session.

In the last one week, shares of Millendo Therapeutics, Inc have increased by +6%.

Millendo Therapeutics, Inc's Key Ratios

Millendo Therapeutics, Inc has a market cap of $0.030 billion, indicating a price to book ratio of 0.6995 and a price to sales ratio of 0.

In the last 12-months Millendo Therapeutics, Inc’s revenue was $0.000 billion with a gross profit of $0.000 billion and an EBITDA of $-0.034 billion. The EBITDA ratio measures Millendo Therapeutics, Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Millendo Therapeutics, Inc’s operating margin was 0% while its return on assets stood at -47.15% with a return of equity of -94.03%.

In Q2, Millendo Therapeutics, Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.

Millendo Therapeutics, Inc’s PE and PEG Ratio

Forward PE
0
Trailing PE
0
PEG
None

Its diluted EPS in the last 12-months stands at $-2.869 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of None. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Millendo Therapeutics, Inc’s profitability.

Millendo Therapeutics, Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of 0.3426. Its price to sales ratio in the trailing 12-months stood at 0.

Millendo Therapeutics, Inc stock pays annual dividends of $None per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$0.000 billion
Total Liabilities
$0.000 billion
Operating Cash Flow
$0.000 billion
Capital Expenditure
$0.000 billion
Dividend Payout Ratio
0%

Millendo Therapeutics, Inc ended 1970 with $0.000 billion in total assets and $131.2 billion in total liabilities. Its intangible assets were valued at $0.000 billion while shareholder equity stood at $0.000 billion.

Millendo Therapeutics, Inc ended 1970 with $0.000 billion in deferred long-term liabilities, $0.000 billion in other current liabilities, billion in common stock, $0.000 billion in retained earnings and $0.000 billion in goodwill. Its cash balance stood at $0.000 billion and cash and short-term investments were $0.000 billion. The company’s total short-term debt was $0.000 billion while long-term debt stood at $0.000 billion.

Millendo Therapeutics, Inc’s total current assets stands at $0.000 billion while long-term investments were $0.000 billion and short-term investments were $0.000 million. Its net receivables were $0.000 billion compared to accounts payable of $0.000 billion and inventory worth $0.000 billion.

In 1970, Millendo Therapeutics, Inc's operating cash flow was $0.000 billion while its capital expenditure stood at $0.000 billion.

Comparatively, Millendo Therapeutics, Inc paid $0 billion in dividends in 1970.

Other key metrics

Current Trading Price
$2.12
52-Week High
$9.88
52-Week Low
$1.26
Analyst Target Price
$4.33

Millendo Therapeutics, Inc stock is currently trading at $2.12 per share. It touched a 52-week high of $9.88 and a 52-week low of $9.88. Analysts tracking the stock have a 12-month average target price of $4.33.

Its 50-day moving average was $0 and 200-day moving average was $0 The short ratio stood at 1.52 indicating a short percent outstanding of 3%.

Around 1130% of the company’s stock are held by insiders while 6547.2% are held by institutions.

Frequently Asked Questions About Millendo Therapeutics, Inc

The stock symbol (also called stock or share ticker) of Millendo Therapeutics, Inc is MLND

The IPO of Millendo Therapeutics, Inc took place on 2012-11-12

Similar Industry Stocks ()

Last Price
Chg
Chg%
$113.23
6.8
+6.39%
$21.69
-10.59
-32.81%
$52.1
-1.86
-3.45%
$6.61
-0.14
-2.07%
$0.53
-0
-0.4%
Synopsys Inc (SNPS)
$281.11
-10.06
-3.46%
$18.77
-0.85
-4.33%
$10.98
-0.12
-1.08%
$2.6
-0.05
-1.89%
$2.62
-0.1
-3.68%

Most Active

Last Price
Chg
Chg%
$58.63
-1.03
-1.73%
$92.12
-4.67
-4.82%
$5.12
-0.61
-10.65%
Apple Inc (AAPL)
$145.03
-5.62
-3.73%
$0.06
0.01
+12.74%

Top Gainers

Last Price
Chg
Chg%
$73
42.7
+140.92%
Oi S.A (OIBR-C)
$0
0
+100%
$0.02
0.01
+100%
$0.25
0.1
+66.44%
$2.85
1.01
+54.86%

Top Losers

Last Price
Chg
Chg%
$5.36
-22.58
-80.82%
$0.02
-0.06
-78.67%
Air T, Inc (AIRTW)
$0.01
-0.03
-75%
$4.51
-5.17
-53.41%
$11.5
-12.2
-51.48%

About

Millendo Therapeutics, Inc., a late-stage biopharmaceutical company, engages in the development of various treatments for orphan endocrine diseases in the United States. The company’s lead product candidates include livoletide, a potential treatment for Prader-Willi syndrome; and nevanimibe, a potential treatment for patients with classic congenital adrenal hyperplasia. Millendo Therapeutics, Inc. is headquartered in Ann Arbor, Michigan.

Address

301 North Main Street, Ann Arbor, MI, United States, 48104